Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MRG003 in EGFR-positive advanced non-small cell lung cancer
CTR20201935Phase 2Active
- Sponsor
- Hangzhou Miracogen
- Start
- Apr 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in non-small cell lung cancer (NSCLC), sponsored by Hangzhou Miracogen. Started Apr 2021; status: active.
02
Drugs
becotatug vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20201935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201935.